Compass Pathways plc rolled out favorable top-line findings from the largest randomized, controlled, double-blind psilocybin therapy study ever completed, showing that COMP-360 at 25 mg yielded a highly statistically significant and clinically relevant reduction in symptom severity after three weeks in patients with treatment-resistant depression (TRD)
.
Upsized IPOs for high-profile psychedelics venture Compass Pathways plc and the neurodegenerative specialist Athira Pharma Inc. debuted on Nasdaq on Sept. 18, climbing fast alongside a forward-looking follow-on offering from cytokine storm fighter Humanigen Inc. Compass (NASDAQ:CMPS) raised $127.5 million, while Athira (NASDAQ:ATHA) brought in $204 million. Humanigen (NASDAQ:HGEN) raised $68 million.
